CCM
FULC icon

Coldstream Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Coldstream Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-105
Closed -$302 – 1934
2025
Q1 		$302 Buy
+105
New +$386 ﹤0.01% 3443

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coldstream Capital Management's FULC Position: Q2 2025 in Review

Coldstream Capital Management sold out of Fulcrum Therapeutics (FULC) in Q2 2025, closing a stake of 105 shares — an estimated $302 sold.

Coldstream Capital Management first reported a position in FULC in Q1 2025 and held it in 1 quarter. The position peaked at $302 in Q1 2025. 122 funds tracked by Wall St. Rank hold FULC as of Q2 2025.

  • Coldstream Capital Management reported no remaining Fulcrum Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 105 Fulcrum Therapeutics shares in Q2 2025, an estimated $302.
  • Coldstream Capital Management first reported a position in Fulcrum Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Fulcrum Therapeutics position peaked at $302 in Q1 2025.
  • 122 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.